Does ENCORAFENIB Cause Second primary malignancy? 115 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 115 reports of Second primary malignancy have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 1.3% of all adverse event reports for ENCORAFENIB.
115
Reports of Second primary malignancy with ENCORAFENIB
1.3%
of all ENCORAFENIB reports
8
Deaths
30
Hospitalizations
How Dangerous Is Second primary malignancy From ENCORAFENIB?
Of the 115 reports, 8 (7.0%) resulted in death, 30 (26.1%) required hospitalization, and 3 (2.6%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 115 reports have been filed with the FAERS database.
What Other Side Effects Does ENCORAFENIB Cause?
Death (1,004)
Off label use (989)
Nausea (758)
Fatigue (685)
Diarrhoea (574)
Neoplasm progression (548)
Pyrexia (539)
Product use in unapproved indication (506)
Vomiting (429)
Rash (414)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ENCORAFENIB Alternatives Have Lower Second primary malignancy Risk?
ENCORAFENIB vs ENDOXAN
ENCORAFENIB vs ENDOXAN BAXTER
ENCORAFENIB vs ENDOXAN INJ
ENCORAFENIB vs ENDOXAN , POUDRE POUR
ENCORAFENIB vs ENFORTUMAB VEDOTIN